Aragen plans to invest US$30 million to setup a new biologics manufacturing facility in Bangalore, India.
The state-of-the-art facility, spanning an impressive area of nearly 160,000 square metres, is an extensive complex designed to cater to a wide range of biologics manufacturing needs.
This facility boasts a range of critical components, including process development laboratories, multiple GMP manufacturing suites, and essential supporting functions such as quality control labs for both analytical and microbiology purposes.
The manufacturing suites within this cutting-edge facility have been purposefully equipped to enable intensified processing, employing single-use bioreactors and advanced downstream purification capabilities.
This facility is set to offer an all-encompassing suite of services, covering everything from process development and validation to analytical development, pilot production, large-scale DS (Drug Substance) manufacturing, and stability services.
It has the capacity and expertise to develop and manufacture a variety of biologics, including monoclonal antibodies (mAbs), therapeutic proteins, and fusion proteins, thereby bolstering its bioproduction capabilities in California.
Furthermore, this facility is designed to include plasmid DNA, mRNA, cell and gene therapy manufacturing, and additional GMP manufacturing suites as demand continues to grow.
The process development laboratory is projected to become operational by the third quarter of 2024, while the first manufacturing suite is scheduled to open in the third quarter of fiscal year 2025.
Type New Construction
Budget US$30 million